Ētahi atu korero ― Maori

Urticaria te nuinga o te wa ka pa mai ki te tino weriweri kua piki ake. I etahi wa ka haere tahi me te pupuhi o nga kopa o raro. Ko te nuinga o te maimoatanga ko te karo i nga kaipatu, mena ka mohiotia. Kei roto i te rongoa tuatahi he antihistamines hou, ka taea te whakatika ki nga pota teitei mena ka hiahiatia. Ko etahi atu rongoa penei i te antihistamines tawhito, te aukati H2, te kaitukino kaikawe leukotriene, te antihistamine kaha ake, me nga akoranga poto o te corticosteroids ka taea te taapiri hei tautoko taapiri. I roto i nga keehi ka mau tonu te urticaria ahakoa enei mahi, ka tukuna pea nga turoro ki nga tohunga mo etahi atu rongoa penei i te omalizumab , cyclosporine # ranei.
Urticaria commonly presents with intensely itchy raised welts. It is sometimes accompanied by swelling of the underlying tissues. Treatment primarily involves avoiding triggers, if known. First-line medication includes newer antihistamines, which can be adjusted to higher doses if needed. Other medications like older antihistamines, H2 blockers, leukotriene receptor antagonists, stronger antihistamines, and short courses of corticosteroids can be added as extra support. In cases where urticaria persists despite these measures, patients might be referred to specialists for additional therapies such as omalizumab or cyclosporine.

Ko tenei arotake e whakaatu ana i nga aratohu hou mo te rongoa i te urticaria me te tuku maarama hou mo ona take.
This review outlines the latest guidelines for treating urticaria and offers new understandings of its causes.

Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), Omalizumab, Ciclosporin, and short courses only of systemic corticosteroids